Affordable Access

deepdyve-link
Publisher Website

Development of Cell-based High Throughput Luminescence Assay for Drug Discovery in Inhibiting OCT4-DNA-PKcs and OCT4-MK2 Interactions.

Authors
  • Mohiuddin, Ismail S1, 2
  • Wei, Sung-Jen1, 2
  • Yang, In-Hyoung1, 2
  • Martinez, Gloria M1, 2
  • Yang, Shengping3
  • Cho, Eun Jeong4
  • Dalby, Kevin N4
  • Kang, Min H1, 2
  • 1 Cancer Center, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX, 79430, USA.
  • 2 Department of Pediatrics, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX, 79430, USA.
  • 3 Biostatistics Department, Pennington Biomedical Research Center, Baton Rouge, LA, 70808, USA.
  • 4 Division of Chemical Biology and Medicinal Chemistry, College of Pharmacy, The University of Texas at Austin, Austin, TX, 78712, USA.
Type
Published Article
Journal
Biotechnology and Bioengineering
Publisher
Wiley (John Wiley & Sons)
Publication Date
Feb 10, 2021
Identifiers
DOI: 10.1002/bit.27712
PMID: 33565603
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Amplification-independent c-MYC overexpression is suggested in multiple cancers. Targeting c-MYC activity has therapeutic potential, but efforts thus far have been mostly unsuccessful. To find a druggable target to modulate c-MYC activity in cancer, we identified two kinases, MAPKAPK2 (MK2) and the DNA-dependent protein kinase catalytic subunit (DNA-PKcs), which phosphorylate the Ser111 and the Ser93 residues of OCT4, respectively, to transcriptionally activate c-MYC. Using these observations, we present here a novel cell-based luminescence assay to identify compounds that inhibit the interaction between these kinases and OCT4. After screening approximately 80,000 compounds, we identified 56 compounds ("hits") that inhibited the luminescence reaction between DNA-PKcs and OCT4, and 65 hits inhibiting the MK2-OCT4 interaction. Using custom antibodies specific for pOCT4S93 and pOCT4S111 , the "hits" were validated for their effect on OCT4 phosphorylation and activation. Using a two-step method for validation, we identified two candidate compounds from the DNA-PKcs assay and three from the MK2 assay. All five compounds demonstrate a significant ability to kill cancer cells in the nanomolar range. In conclusion, we developed a cell-based luminescence assay to identify novel inhibitors targeting c-MYC transcriptional activation, and have found five compounds that may function as lead compounds for further development. This article is protected by copyright. All rights reserved. This article is protected by copyright. All rights reserved.

Report this publication

Statistics

Seen <100 times